Public Release: 

New reagents for genomic engineering of mouse models to understand human disease

A new set of tools allow researchers to specifically target DNA changes through genetic recombination in mice

The Company of Biologists

The ability to specifically target and modify genes in the mouse allows researchers to use this small rodent to study how certain genes contribute to human disease. A common method used to make genetic changes in mice and cells is called site-specific recombination, where two DNA strands are exchanged. The two strands may contain very different sequences, but are designated at their ends by specific target sequences that are not commonly found elsewhere in the genome. A protein, called a recombinase, cuts the DNA at its target sites and rearranges it. Scientists use this technique to exchange a naturally occurring DNA sequence for an altered or deleted gene to gain insight into the gene's normal function or how it contributes to disease.

Currently there are a few systems available to create genetic mutations in mice, including the recombinases FLP and Cre. These proteins are very efficient genetic modifiers and specifically target their appropriate sequences. They can also be turned on or off at precise times, or within specific tissues, to make carefully reegulated genetic changes. However, the small number of available methods that can be used together to mutate genes limits the complexity of the modifications that can be produced. For example, it would be informative to independently regulate the temporal and tissue-specific expression of genes with overlapping functions to understand their individual and combined effects.

Scientists now report that a new recombinase, Dre, induces controlled genetic changes in mice. Dre works similarly to the currently popular recombinase Cre, with an important exception: Dre recognizes a distinct target sequence and only recombines DNA around its target sequence, even if the target sequence for Cre is present. The ability of the related proteins, Cre and Dre to distinguish their own target sequences indicates that Dre can be used in combination with Cre, and other recombinases, to produce more sophisticated mouse models. This should facilitate the analysis of complex gene interactions and how they function in disease.

This technological advance also highlights the progress that might be made through open reagent sharing within the scientific community. The discovery of Dre recombinase was originally reported by Sauer and McDermott at the Stowers Institute for Medical Research. The Institute holds an intellectual patent for the system that allows it to be shared openly for non-commercial purposes and evaluates requests on a case-by-case basis for its use by for-profit institutions. Thus, the authors of the new DMM report do not have any proprietary claims to the system that they used to create this valuable mouse model. This is the first of a series of Resource Articles that will appear in Disease Models and Mechanisms intended to promote collaboration, and the development and sharing of new tools to understand or treat human disease. These DMM articles specifically state how other researchers can access the reagents presented. More discussion about the sharing of scientific resources and collaboration is published in an editorial by the Editor-in-Chief, Vivian Siegel, in Volume 2 Issue 9/10 of DMM.

###

This first Resource Article titled 'Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice' was written by Konstantinos Anastassiadis at the Center for Regenerative Therapies Dresden, BioInnovationsZentrum Technische Universitaet Dresden; Jun Fu at Genomics, BioInnovationsZentrum, Technische Universitaet Dresden; Christoph Patsch at the Institute of Reconstructive Neurobiology, University of Bonn; Shengbiao Hu at Genomics, BioInnovationsZentrum, Technische Universitaet Dresden; Stefanie Weidlich at the Center for Regenerative Therapies Dresden, BioInnovationsZentrum Technische Universitaet Dresden; Kristin Duerschke at Genomics, BioInnovationsZentrum, Technische Universitaet Dresden; Frank Buchholz at the Max-Planck-Institute for Molecular Cell Biology and Genetics; Frank Edenhofer at the Institute of Reconstructive Neurobiology, University of Bonn; and A. Francis Stewart at Genomics, BioInnovationsZentrum, Technische Universitaet Dresden. The study is published in the September/October 2009 issue of the new research journal, Disease Models & Mechanisms (DMM), <http://dmm.biologists.org/>, published by The Company of Biologists, a non-profit organization based in Cambridge, UK.

About Disease Models & Mechanisms:

Disease Models & Mechanisms (DMM) is a new research journal, launched in 2008, that publishes primary scientific research, as well as review articles, editorials, and research highlights. The journal's mission is to provide a forum for clinicians and scientists to discuss basic science and clinical research related to human disease, disease detection and novel therapies. DMM is published by the Company of Biologists, a non-profit organization based in Cambridge, UK.

The Company also publishes the international biology research journals Development, Journal of Cell Science, and The Journal of Experimental Biology. In addition to financing these journals, the Company provides grants to scientific societies and supports other activities including travelling fellowships for junior scientists, workshops and conferences. The world's poorest nations receive free and unrestricted access to the Company's journals.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.